Hoffmann-La Roche Matches Revenue Expectations Despite Pharma Sales Dip
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FactSet released the latest sales figures for Hoffmann-La Roche. The company matched Wall Street's revenue expectations and reaffirmed its guidance for the year. Ocrevus, Hoffmann-La Roche's largest revenue generator, produced $2.25 billion in third-quarter sales, which was in line with forecasts. However, overall pharmaceutical sales totaled $14.85 billion, missing the $14.9 billion estimate.
From investors.com
Why it matters
Hoffmann-La Roche's ability to meet revenue expectations allowed the company to maintain its guidance despite a shortfall in overall pharmaceutical sales. The strong performance of Ocrevus, its biggest moneymaker, was consistent with market predictions.
From investors.com
Who's involved
- FactSetAmerican financial data company that reported the sales figures
- Hoffmann-La RocheSwiss healthcare company whose third-quarter sales were reported
Keep exploring
The entities involved
-
FactSet
American financial data company
-
Hoffmann-La Roche
Swiss healthcare company